## REMARKS

In response to the Restriction Requirement dated June 29, 2006, Applicants elect the invention of Group II, claims 5-14, 39 and 42, drawn to a nucleic acid, and Applicants further elect the nucleic acid sequence of SEQ ID NO: 143, without traverse.

Upon entry of the present amendment, claims 5-14, 39 and 42 are pending. Claims 1-4, 15-38, 40, 41 and 43-49 have been withdrawn. Applicants reserve the right to prosecute that subject matter, as well as the originally presented claims, in continuing applications. Claims 5, 8, 9 and 10 have been amended. Support for the amendments presented herein is found throughout the specification and claims as originally filed. For example, support for the amendments is found at least at pages 321-333. Accordingly, no new matter has been added by the claim amendments presented herein.

## **CONCLUSION**

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and/or these remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

LN: Kypr R. Elrifi, Reg. No. 39,529

Attorney for Applicants c/o MINTZ, LEVIN Tel: (617) 542-6000

Fax: (617) 542-2241 Customer No.: **55111** 

TRA 2203743v.1